Category News

United Therapeutics

United Therapeutics Launches $1 Billion Accelerated Stock Buyback Program

United Therapeutics Launches $1 Billion Accelerated Share Repurchase Initiative, Underscoring Confidence in Long-Term Growth and Shareholder Value In a bold affirmation of its robust financial health, strategic vision, and shareholder-centric philosophy, United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation…

Read MoreUnited Therapeutics Launches $1 Billion Accelerated Stock Buyback Program
Arrowhead

Arrowhead’s Subsidiary Visirna Sells China Rights for Plozasiran to Sanofi

Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape for patients with severe lipid disorders in China, Arrowhead Pharmaceuticals,…

Read MoreArrowhead’s Subsidiary Visirna Sells China Rights for Plozasiran to Sanofi

EC Approves CAR-T Therapy Using AGC Biologics’ Lentiviral Vectors

European Commission Greenlights AUCATZYL®: AGC Biologics Marks 10th Regulatory Approval with Autolus’ CAR-T Therapy AGC Biologics, a global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies, has reached another significant milestone. On July 21, the European…

Read MoreEC Approves CAR-T Therapy Using AGC Biologics’ Lentiviral Vectors

Actio Biosciences Secures FDA IND Clearance and Fast Track for ABS-1230 in KCNT1 Epilepsy

Actio Biosciences Receives FDA IND Clearance and Fast Track Designation for ABS-1230 in KCNT1-Related Epilepsy, Marking Major Advancement in Pediatric Precision Medicine Actio Biosciences, a clinical-stage biotechnology company pioneering novel therapies through the lens of genetics and precision medicine, has…

Read MoreActio Biosciences Secures FDA IND Clearance and Fast Track for ABS-1230 in KCNT1 Epilepsy

Avance Clinical Enhances Trial Compliance and Integrity Through ValGenesis Partnership

Avance Clinical Ushers in a New Era of Trial Excellence Through Strategic Digital Validation Partnership with ValGenesis In a strategic move set to redefine the landscape of clinical research quality management, Avance Clinical, a globally recognized Australian contract research organization…

Read MoreAvance Clinical Enhances Trial Compliance and Integrity Through ValGenesis Partnership

BeOne Medicines Secures CHMP Backing for TEVIMBRA® in Neoadjuvant and Adjuvant NSCLC Use

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Early-Stage Lung Cancer, Expanding Its Role in Perioperative NSCLC Treatment BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company committed to transforming cancer care through next-generation immunotherapy,…

Read MoreBeOne Medicines Secures CHMP Backing for TEVIMBRA® in Neoadjuvant and Adjuvant NSCLC Use

DiaMedica Therapeutics Closes $30.1 Million Private Placement to Advance Clinical Programs

DiaMedica Therapeutics Secures $30.1 Million in Oversubscribed Private Placement to Bolster Advancement of Neurological and Maternal Health Pipeline Proceeds strengthen company’s financial runway as it targets innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke DiaMedica Therapeutics Inc.…

Read MoreDiaMedica Therapeutics Closes $30.1 Million Private Placement to Advance Clinical Programs

Flatiron Health Triples Global Oncology Network to Boost Multinational Research

Flatiron Health Triples Global Oncology Research Network to Power Multinational Real-World Evidence Generation Flatiron Health, a healthtech company pioneering the use of real-world data (RWD) to transform cancer care and accelerate oncology research, has announced a significant milestone: the tripling…

Read MoreFlatiron Health Triples Global Oncology Network to Boost Multinational Research

YourChoice Therapeutics Celebrates Second Publication in Nature

YourChoice Therapeutics Advances Male Contraception with Second Nature Portfolio Publication Showcasing Human Trial Data for YCT-529 YourChoice Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of hormone-free contraceptive solutions, has announced a significant milestone with the publication of its…

Read MoreYourChoice Therapeutics Celebrates Second Publication in Nature